HR
OVID icon

Howe & Rusling’s Ovid Therapeutics OVID Stock Holding History

Howe & Rusling’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-180
Closed -$1K – 1006
2021
Q1 		$1K Hold
180
– – ﹤0.01% 899
2020
Q4 		$0 Hold
180
– – ﹤0.01% 985
2020
Q3 		$1K Hold
180
– – ﹤0.01% 788
2020
Q2 		$1K Buy
+180
New +$842 ﹤0.01% 759

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Howe & Rusling's OVID Position: Q2 2021 in Review

Howe & Rusling sold out of Ovid Therapeutics (OVID) in Q2 2021, closing a stake of 180 shares — an estimated $1K sold.

Howe & Rusling first reported a position in OVID in Q2 2020 and held it in 4 quarters. The position peaked at $1K in Q1 2021. 80 funds tracked by Wall St. Rank hold OVID as of Q2 2021.

  • Howe & Rusling reported no remaining Ovid Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Howe & Rusling sold 180 Ovid Therapeutics shares in Q2 2021, an estimated $1K.
  • Howe & Rusling first reported a position in Ovid Therapeutics in Q2 2020 and held it in 4 quarters.
  • Howe & Rusling's Ovid Therapeutics position peaked at $1K in Q1 2021.
  • 80 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2021.

Based on Howe & Rusling's 13F filing for Q2 2021, filed 13 Aug 2021.